Business Wire

QUECTEL-WIRELESS

14.3.2023 09:02:03 CET | Business Wire | Press release

Share
Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices

Quectel Wireless Solutions, a global IoT solutions provider, today announces Quectel Certification Services, its range of IoT device certification and testing services that will enable customers to rapidly certify their IoT devices with regulatory organisations such as the FCC, IC, CE, ANATEL, RCM, KC, Jate and Telec and carrier organisations including AT&T, Verizon, T-Mobile, Rogers, TELUS and Vodafone. This service will enable customers’ devices to gain certifications in under eight weeks and is not only the fastest time to market for IoT device manufacturers, but also the industry’s most cost-effective offering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005140/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices (Photo: Business Wire)

Certification across these disciplines is complex to achieve, involves multiple layers of certification from disparate organisations and, typically, local and regional authorities award certifications for device deployments in their own territories. The Quectel Certification Services span regulatory, conformance and carrier compliance requirements plus certifications for industry-specific devices and environmental and safety-related certifications, such as such as ATmosphere EXplosible (ATEX), Restriction of Hazardous Substances (RoHS), Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and waste electrical and electronic equipment (WEEE).

“Going directly to certification or carrier organizations can result in it taking up to six months for IoT devices to gain certifications,” said Yoon Seungryoul, North American Certification Director, Quectel Wireless Solutions. “For many IoT use cases a six-month delay to launch is unacceptable and could make or break a proposition in markets where being first-to-launch is a critical differentiator. This is why Quectel, with our Quectel Certification Services, is bringing to customers our existing knowledge of certification and testing processes and our relationships with authorities, certification bodies, regulators, and carriers to provide our customers with the industry’s fastest and most cost-effective go-to-market offering.”

To further help customers, Quectel Certification Services offers a pre-scan service in its own labs so certification compliance can be assessed before applying to certification authorities, thereby saving time on non-compliant certification applications. A further benefit for customers that utilize both Quectel modules and antennas in their design, is that device testing is included for free. Quectel also offers technical support facilities and debugging solutions to address common, and not so common, certification issues.

Quectel’s capabilities include project management, administration, lab and carrier communications and management, checking and managing test scope, providing the necessary on-site support, and providing testing and debugging. In addition, Quectel will fix issues as they arise and negotiate waivers where appropriate.

“We’re proud to have launched Quectel Certification Services and we’re ready to provide full, global certification consultation and service to integrated device customers that have products that are based on Quectel modules,” added Seungryoul. “Quectel Certification Services have been gaining certifications for Quectel’s own modules and customers’ devices for many years, so we’re delighted to be bringing this expertise to customers and helping them accelerate time-to-market and build a smarter world.”

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005140/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye